ArticleBMC public health2025
Electronic cigarette use and risk of chronic kidney disease: a dose-response analysis with propensity score matching in a nationally representative cohort.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Influence of the Main Components of Tobacco Smoke, E-Cigarettes, and Air Pollutants on the Development of Glomerulonephritis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe long-term renal effects of electronic cigarette (e-cigarette) use remain poorly understood, despite its global rise as a nicotine delivery system. This study investigates the association between e-cigarette use and chronic kidney disease (CKD), with emphasis on dose-response relationships, subgroup heterogeneity, and adjustment for cigarette smoking.
methodsWe analyzed data from 872 adults in NHANES (2017-2020). E-cigarette use was categorized by self-reported frequency (non-users, 1-2 days/week, ≥ 3 days/week). CKD was defined as urinary albumin-to-creatinine ratio ≥ 30 mg/g. Weighted multivariable logistic regression models adjusted for age, gender, race, BMI, diabetes, hypertension, and current cigarette smoking. Propensity score matching (PSM, 1:1) balanced baseline covariates, including current smoking. Dose-response trends were assessed via restricted cubic splines (RCS).
resultsAmong 188 e-cigarette users and 684 non-users, users were significantly younger and had higher serum cotinine. In fully adjusted models (Model 3), e-cigarette use was associated with a 2.50-fold higher odds of CKD (95% CI: 1.80-3.48, P < 0.001). A significant dose-response relationship existed: adjusted ORs for CKD were 1.80 (95% CI: 1.20-2.70) for 1-2 days/week and 2.60 (95% CI: 1.70-4.00) for ≥ 3 days/week use (P-trend = 0.002). This association was significantly stronger in non-diabetics (OR = 2.40, 95% CI: 1.65-3.50) vs. diabetics (P-interaction = 0.032) and in current smokers (OR = 2.35, 95% CI: 1.55-3.56) vs. non-smokers (P-interaction = 0.021). Sensitivity analyses confirmed robustness: PSM yielded OR = 1.89 (95% CI: 1.18-3.01, P = 0.009); excluding dual users yielded OR = 1.98 (95% CI: 1.28-3.06, P = 0.003); and cotinine-based exposure yielded OR = 2.25 (95% CI: 1.43-3.54, P = 0.001).
conclusionE-cigarette use is independently associated with CKD in a dose-dependent manner, particularly among non-diabetic individuals. Notably, NHANES data limitations include lack of past e-cigarette use or smoking history records, which may introduce residual confounding. These findings highlight vaping as a modifiable risk factor for kidney disease, urging targeted public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.